HomeCompareCBAUF vs PFE

CBAUF vs PFE: Dividend Comparison 2026

CBAUF yields 2.77% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $22.4K in total portfolio value· pulled ahead in Year 9
10 years
CBAUF
CBAUF
● Live price
2.77%
Share price
$119.83
Annual div
$3.32
5Y div CAGR
10.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.1K
Annual income
$974.69
Full CBAUF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — CBAUF vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCBAUFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CBAUF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CBAUF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CBAUF
Annual income on $10K today (after 15% tax)
$235.77/yr
After 10yr DRIP, annual income (after tax)
$828.49/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $21,491.42/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CBAUF + PFE for your $10,000?

CBAUF: 50%PFE: 50%
100% PFE50/50100% CBAUF
Portfolio after 10yr
$38.4K
Annual income
$13,616.71/yr
Blended yield
35.50%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

CBAUF
No analyst data
Altman Z
-0.5
Piotroski
6/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CBAUF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCBAUFPFE
Forward yield2.77%6.13%
Annual dividend / share$3.32$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR10.2%13.2%
Portfolio after 10y$27.1K$49.6K
Annual income after 10y$974.69$26,258.71
Total dividends collected$5.8K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CBAUF vs PFE ($10,000, DRIP)

YearCBAUF PortfolioCBAUF Income/yrPFE PortfolioPFE Income/yrGap
1$11,006$305.66$9,153$693.39+$1.9KCBAUF
2$12,123$346.46$8,593$849.25+$3.5KCBAUF
3$13,364$393.04$8,336$1,066.78+$5.0KCBAUF
4$14,746$446.25$8,437$1,384.80+$6.3KCBAUF
5$16,285$507.11$9,013$1,875.40+$7.3KCBAUF
6$18,002$576.80$10,306$2,680.72+$7.7KCBAUF
7$19,919$656.67$12,820$4,101.38+$7.1KCBAUF
8$22,061$748.33$17,673$6,826.70+$4.4KCBAUF
9← crossover$24,459$853.61$27,543$12,591.86$3.1KPFE
10$27,146$974.69$49,560$26,258.71$22.4KPFE

CBAUF vs PFE: Complete Analysis 2026

CBAUFStock

Commonwealth Bank of Australia provides integrated financial services in Australia, New Zealand, and internationally. It operates through Retail Banking Services, Business Banking, Institutional Banking and Markets, and New Zealand segments. The company offers transaction, savings, and foreign currency accounts; term deposits; personal and business loans; overdrafts; equipment finance; credit cards; international payment and trade; and private banking services, as well as home and car loans. It also provides retail, premium, business, offshore, and institutional banking services; and funds management, superannuation, and share broking products and services, as well as car, health, life, income protection, and travel insurance. The company offers advisory services for high-net-worth individuals; equities trading and margin lending services; debt capital, transaction banking, working capital, and risk management services; and international and foreign exchange services. As of June 30, 2022, it operated 807 branches/service centres and 2,095 ATMs. The company was founded in 1911 and is based in Sydney, Australia.

Full CBAUF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this CBAUF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CBAUF vs SCHDCBAUF vs JEPICBAUF vs OCBAUF vs KOCBAUF vs MAINCBAUF vs JNJCBAUF vs MRKCBAUF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.